6 assets in Vaginal Neoplasm

Therapeutic assets addressing Vaginal Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Vaginal Neoplasm	Yonsei University	P2	CCC (53)
Dostarlimab Vaginal Neoplasm	Yonsei University	P2	CCC (53)
Nivolumab Vaginal Neoplasm	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Cyclophosphamide Vaginal Neoplasm	HRYZ Biotech Co.	P1	CC (43)
Fludarabine Vaginal Neoplasm	HRYZ Biotech Co.	P1	CC (43)
Hryz-T101 Tcr-T Cell Vaginal Neoplasm	HRYZ Biotech Co.	P1	CC (43)